U.S. FDA Approves New Indication for Merck's PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients

PREVYMIS now approved for CMV prophylaxis after kidney transplant in Donor CMV-seropositive/Recipient CMV-seronegative patients

... | June 6, 2023

Related Keywords

United States ,Alaska ,Japan ,Canada ,China ,American ,Alaskan ,Elizabeth Rhee ,Linkedin ,Statement Of Merck Co Inc ,Youtube ,Merck Research Laboratories ,Instagram ,Merck Co Inc ,Facebook ,Drug Administration ,Twitter ,Aicuris Gmbh Co ,Exchange Commission ,Selected Safety Information ,Merck Research ,American Indian ,Child Pugh Class ,Aicuris Gmbh ,Safety Information ,Prescribing Information ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Merck Co ,Nc Stock Exchange ,News ,Information ,Press Release ,Revymis ,Dow ,Approved ,Or ,Dmv ,Prophylaxis ,After ,Kidney ,Transplant ,N ,Onor Mrk Us58933y1055 ,